tetano
Editor, Senior Moderator
BMC Pulm Med
. 2022 Nov 14;22(1):418.
doi: 10.1186/s12890-022-02230-5.
Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma
Thomas R Murphy[SUP] 1 [/SUP], William Busse[SUP] 2 [/SUP], Cecile T J Holweg[SUP] 3 [/SUP], Yamina Rajput[SUP] 3 [/SUP], Karina Raimundo[SUP] 3 [/SUP], Craig S Meyer[SUP] 3 [/SUP], Arpamas Seetasith[SUP] 4 [/SUP], Sachin Gupta[SUP] 3 [/SUP], Ahmar Iqbal[SUP] 3 [/SUP], Robert J Kaner[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Although asthma does not appear to be a risk factor for severe coronavirus disease 2019 (COVID-19), outcomes could vary for patients with different asthma subtypes. The objective of this analysis was to compare COVID-19 outcomes in real-world cohorts in the United States among patients with asthma, with or without evidence of allergy.
Methods: In a retrospective analysis of the COVID-19 Optum electronic health record dataset (February 20, 2020-January 28, 2021), patients diagnosed with COVID-19 with a history of moderate-to-severe asthma were divided into 2 cohorts: those with evidence of allergic asthma and those without (nonallergic asthma). After 1:1 propensity score matching, in which covariates were balanced and potential bias was removed, COVID-19 outcomes were compared between cohorts.
Results: From a COVID-19 population of 591,198 patients, 1595 patients with allergic asthma and 8204 patients with nonallergic asthma were identified. After propensity score matching (n = 1578 per cohort), risk of death from any cause after COVID-19 diagnosis was significantly lower for patients with allergic vs nonallergic asthma (hazard ratio, 0.48; 95% CI 0.28-0.83; P = 0.0087), and a smaller proportion of patients with allergic vs nonallergic asthma was hospitalized within - 7 to + 30 days of COVID-19 diagnosis (13.8% [n = 217] vs 18.3% [n = 289]; P = 0.0005). Among hospitalized patients, there were no significant differences between patients with allergic or nonallergic asthma in need for intensive care unit admission, respiratory support, or COVID-19 treatment.
Conclusions: Asthma subtype may influence outcomes after COVID-19; patients with allergic asthma are at lower risk for hospitalization/death than those with nonallergic asthma.
Keywords: Allergic asthma; Allergy; Asthma; Atopic; COVID-19; Coronavirus; Nonallergic asthma; Pandemic; Respiratory; SARS-CoV-2.
. 2022 Nov 14;22(1):418.
doi: 10.1186/s12890-022-02230-5.
Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma
Thomas R Murphy[SUP] 1 [/SUP], William Busse[SUP] 2 [/SUP], Cecile T J Holweg[SUP] 3 [/SUP], Yamina Rajput[SUP] 3 [/SUP], Karina Raimundo[SUP] 3 [/SUP], Craig S Meyer[SUP] 3 [/SUP], Arpamas Seetasith[SUP] 4 [/SUP], Sachin Gupta[SUP] 3 [/SUP], Ahmar Iqbal[SUP] 3 [/SUP], Robert J Kaner[SUP] 5 [/SUP]
Affiliations
- PMID: 36376851
- DOI: 10.1186/s12890-022-02230-5
Abstract
Background: Although asthma does not appear to be a risk factor for severe coronavirus disease 2019 (COVID-19), outcomes could vary for patients with different asthma subtypes. The objective of this analysis was to compare COVID-19 outcomes in real-world cohorts in the United States among patients with asthma, with or without evidence of allergy.
Methods: In a retrospective analysis of the COVID-19 Optum electronic health record dataset (February 20, 2020-January 28, 2021), patients diagnosed with COVID-19 with a history of moderate-to-severe asthma were divided into 2 cohorts: those with evidence of allergic asthma and those without (nonallergic asthma). After 1:1 propensity score matching, in which covariates were balanced and potential bias was removed, COVID-19 outcomes were compared between cohorts.
Results: From a COVID-19 population of 591,198 patients, 1595 patients with allergic asthma and 8204 patients with nonallergic asthma were identified. After propensity score matching (n = 1578 per cohort), risk of death from any cause after COVID-19 diagnosis was significantly lower for patients with allergic vs nonallergic asthma (hazard ratio, 0.48; 95% CI 0.28-0.83; P = 0.0087), and a smaller proportion of patients with allergic vs nonallergic asthma was hospitalized within - 7 to + 30 days of COVID-19 diagnosis (13.8% [n = 217] vs 18.3% [n = 289]; P = 0.0005). Among hospitalized patients, there were no significant differences between patients with allergic or nonallergic asthma in need for intensive care unit admission, respiratory support, or COVID-19 treatment.
Conclusions: Asthma subtype may influence outcomes after COVID-19; patients with allergic asthma are at lower risk for hospitalization/death than those with nonallergic asthma.
Keywords: Allergic asthma; Allergy; Asthma; Atopic; COVID-19; Coronavirus; Nonallergic asthma; Pandemic; Respiratory; SARS-CoV-2.